Trial Profile
Phase 1b/2 Study of ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs ETBX 011 (Primary) ; Inbakicept (Primary)
- Indications Colon cancer; Rectal cancer
- Focus Adverse reactions
- Sponsors ImmunityBio; NantCell
- 23 Aug 2019 Status changed from active, no longer recruiting to completed.
- 04 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 14 Sep 2017 Status changed from not yet recruiting to recruiting.